Role of MYCN in retinoblastoma

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 270-271

  Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN MYCN; PROTEIN RB1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

GENE ACTIVATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; LETTER; LOSS OF FUNCTION MUTATION; MYCN GENE; ONCOGENE; PRIORITY JOURNAL; RB1 GENE; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

FEMALE; GENE DOSAGE; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 84875812914     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70070-6     Document Type: Letter

References (9)

1. Bishop JM Molecular themes in oncogenesis. Cell 1991, 64:235-248.
2. Murphree AL, Benedict WF Retinoblastoma: clues to human oncogenesis. Science 1984, 223:1028-1033.
3. Knudson A Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
4. Hanahan D, Weinberg R Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Weinstein IB, Joe A Oncogene addiction. Cancer Res 2008, 68:3077-3080.
6. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013, published online March 13. http://dx.doi.org/10.1016/S1470-2045(13)70045-7.
7. Nevins JR The Rb/E2F pathway and cancer. Hum Mol Genet 2011, 10:699-703.
8. Arvanitis C, Felsher DW Conditionally MYC: insights from novel transgenic models. Cancer Lett 2005, 226:95-99.
9. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.